Partner Content Partner Content Four weeks until Adaptive Designs in Clinical Trials Confere... Four weeks until SMi’s 11th Annual Conference
Partner Content Partner Content Pfizer’s vice president & Head of Early Clinical Develop... Adaptive Designs in Clinical Trials 2019
Partner Content Partner Content Registration opens for the 11th Adaptive Designs in Clinical... Adaptive Designs in Clinical Trials 2019
News Otsuka eyes early filing of IgAN drug after phase 3 readout Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.